Neutron Therapeutics

Neutron Therapeutics is a private, clinical-stage company pioneering the development and commercialization of hospital-based Boron Neutron Capture Therapy (BNCT) systems. The company has established itself as a leader in the field, with multiple systems shipped and installed internationally, including the first accelerator-based BNCT platform in Europe at Helsinki University Hospital. While its lead system, the nuBeam BNCT Suite, remains investigational and not yet approved by the FDA or PMDA, the company has progressed to treating head and neck cancer patients in clinical settings abroad. Neutron Therapeutics operates in a high-potential but nascent radiotherapy niche, facing significant regulatory and commercial adoption hurdles.

nuBeam BNCT Suite: A compact, accelerator-based neutron source designed for in-hospital installation to enable Boron Neutron Capture Therapy (BNCT). The system generates a high-flux neutron beam via a lithium target reaction for targeted, cellular-level radiation therapy.

BNCT is a niche field with few commercial players. Competition includes other companies developing accelerator-based BNCT systems, primarily in Japan (e.g., Stella Pharma, Sumitomo Heavy Industries) and China. Neutron Therapeutics differentiates with its focus on a compact, hospital-integrated suite and early international installations.